Elsevier has announced that the London university UCL has subscribed to PharmaPendium, part of Elsevier's R&D Solutions for Pharma and Life Sciences.

PharmaPendium is a decision support solution designed to help improve drug development decisions by enabling access to the most comprehensive resource of fully searchable FDA/EMA drug approval documents and associated comparative extracted databases. PharmaPendium is now available to students and researchers in UCL's recently created Clinical Pharmacology and Therapeutics group.

UCL selected PharmaPendium to support the work of students and the projects of various research groups, including research into drug repurposing and personalized treatments. Researchers at UCL will use PharmaPendium to evaluate dosing regimens and explore the potential for optimizing the efficacy-safety profile of currently approved medicines.

'Finding information that reflects regulatory insight and requirements in order to uncover repurposing opportunities and to suggest new personalised dosing regimens can be a challenge,' said Oscar Della Pasqua, chair of Clinical Pharmacology and Therapeutics at UCL.

'With PharmaPendium, our researchers can get a full picture of the clinical development process, including access to the regulatory data used to support the filing and approval of medicinal product. Results can be obtained far quicker because of the data structure and targeted keyword search feature. We chose PharmaPendium as it offered a depth of data that no other solution could match. Ultimately, it fully supports the cutting edge research that we carry out at UCL.'